Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jul 31:2019:2975631.
doi: 10.1155/2019/2975631. eCollection 2019.

A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab

Ted George Achufusi  1 , Prateek S Harnee  1 , Sekou Rawlins  2
Affiliations
Case Reports

A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab

Ted George Achufusi et al. Case Rep Med. .

Erratum in

Abstract

Secukinumab is an IgG monoclonal antibody widely used for treatment of ankylosing spondylitis, psoriasis, and psoriatic arthritis. Recently, there has been increasing controversy regarding potential adverse effects of the drug especially in those with underlying inflammatory bowel disease. We present the case of a young male patient who developed severe new-onset ulcerative colitis following initiation of secukinumab for psoriasis, with excellent response and rapid resolution of symptoms with infliximab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Endoscopic evaluation demonstrating severe colitis throughout the colon.
Figure 2
Figure 2
Histological features. (a, b) Distortion of the crypt architecture, inflammation of crypts (cryptitis), frank crypt abscesses, and hemorrhage or inflammatory cells in the lamina propria. (c) Intense inflammation of the mucosa is seen. (d) The colonic mucosal epithelium demonstrates loss of goblet cells. The shape of the crypts is distorted. Also, there are features of early dysplasia towards the bottom of the crypts as seen by the deep staining and crowded nuclei.
See this image and copyright information in PMC

References

    1. Fitzpatrick L. R. Inhibition of IL-17 as a pharmacological approach for IBD. International Reviews of Immunology. 2013;32(5-6):544–555. doi: 10.3109/08830185.2013.821118. - DOI - PubMed
    1. Hueber W., Patel D. D., Dryja T., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Science Translational Medicine. 2010;2(52):p. 52ra72. doi: 10.1126/scitranslmed.3001107. - DOI - PubMed
    1. Hohenberger M., Cardwell L. A., Oussedik E., Feldman S. R. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. Journal of Dermatological Treatment. 2018;29(1):13–18. doi: 10.1080/09546634.2017.1329511. - DOI - PubMed
    1. Ehrlich D., Jamaluddin N., Pisegna J., Padua D. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Reports in Gastrointestinal Medicine. 2018;2018:4. doi: 10.1155/2018/9679287.9679287 - DOI - PMC - PubMed
    1. Wang J., Bhatia A., Cleveland N., et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Reports Journal. 2018;5(1):p. e56. doi: 10.14309/crj.2018.56. - DOI - PMC - PubMed

Publication types